Show simple item record

dc.contributor.authorKozanoğlu, İlknur
dc.contributor.authorKartal Yandım, Melis
dc.contributor.authorÇinçin, Zeynep Birsu
dc.contributor.authorÖzdoğu, Hakan
dc.contributor.authorÇakmakoğlu, Bedia
dc.contributor.authorBaran, Yusuf
dc.date.accessioned2017-04-19T07:14:12Z
dc.date.available2017-04-19T07:14:12Z
dc.date.issued2013-02
dc.identifier.citationKozanoğlu, I., Kartal Yandım, M., Çinçin, Z.B., Özdoğu, H., Çakmakoğlu, B., and Baran, Y. (2013). New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. Journal of Cancer Research and Clinical Oncology, 139(2), 327-335. doi:10.1007/s00432-012-1331-yen_US
dc.identifier.issn0171-5216
dc.identifier.urihttps://doi.org/10.1007/s00432-012-1331-y
dc.identifier.urihttp://hdl.handle.net/11147/5343
dc.description.abstractPurpose: Propranolol, a non-selective β-adrenergic receptor blocker, has been used for the treatment of the patients with hypertension for more than 50 years. There are several in vitro and in vivo evidences that β-adrenergic receptor antagonists inhibit proliferation and angiogenesis and also increase apoptosis in breast, skin, and colon cancers. The aim of this study was to investigate the cytotoxic and apoptotic effects of propranolol and the genes involved in propranolol-induced apoptosis in multiple myeloma cells. Methods: Time-dependent antiproliferation and apoptotic effects of propranolol were subsequently determined by MTT cell proliferation assay, changes in caspase-3 activity, loss of mitochondrial membrane potential (MMP), and also the localization of phosphatidylserine in the plasma membrane. Changes in expression levels of NF-ΚB pathway were examined by qRT-PCR array. Results: IC50 values of propranolol on U266 cells were calculated as 141, 100, and 75 μM after 24-, 48-, and 72-h propranolol exposure, respectively. There were significant increases in caspase-3 activity, loss of MMP, and increases in apoptotic cell population in response to propranolol in U266 cells in a time- and dose-dependent manner. There were increases in expression levels of BCL10, TRAF family members, interleukins, TLR1-4, TNFRSF10B, NF-κB, and the inhibitors of NF-κB genes, and significant decreases in expression levels of Bcl-2 in response to propranolol treatment were observed. Conclusion: These results revealed that propranolol has antiproliferative and apoptotic effects on multiple myeloma cells. Being supported with in vivo analyses, propranolol can be a good and economical way to treat multiple myeloma patients.en_US
dc.description.sponsorshipTurkish Academy of Sciences Outstanding Young Investigator Programmeen_US
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.relation.isversionof10.1007/s00432-012-1331-yen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectApoptosisen_US
dc.subjectMultiple myelomaen_US
dc.subjectNF-κB pathwayen_US
dc.subjectPropranololen_US
dc.subjectCanceren_US
dc.subjectDrug cytotoxicityen_US
dc.titleNew indication for therapeutic potential of an old well-known drug (propranolol) for multiple myelomaen_US
dc.typearticleen_US
dc.contributor.authorIDTR119193en_US
dc.contributor.iztechauthorKartal Yandım, Melis
dc.contributor.iztechauthorBaran, Yusuf
dc.relation.journalJournal of Cancer Research and Clinical Oncologyen_US
dc.contributor.departmentİYTE, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümüen_US
dc.identifier.volume139en_US
dc.identifier.issue2en_US
dc.identifier.startpage327en_US
dc.identifier.endpage335en_US
dc.identifier.wosWOS:000313827600018
dc.identifier.scopusSCOPUS:2-s2.0-84874992804
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record